Can Hypofractionation and Immune Modulation Coexist?

Affiliations

¹ Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
² Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom; Department of Clinical Oncology, Mount Vernon Cancer Centre, Northwood, United Kingdom.
³ Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. Electronic address: ananya.choudhury@nhs.net.

Editorial

Richard C Walshaw et al. Int J Radiat Oncol Biol Phys. 2021.

. 2021 Jul 1;110(3):742-744.

doi: 10.1016/j.ijrobp.2021.02.052.

¹ Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
² Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom; Department of Clinical Oncology, Mount Vernon Cancer Centre, Northwood, United Kingdom.
³ Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. Electronic address: ananya.choudhury@nhs.net.

Erratum in

Erratum to: Walshaw RC, Hoskin PJ, Choudhury A. Can Hypofractionation and Immune Modulation Coexist? Int J Radiat Oncol Biol Phys 2021;110(3):742-744.
[No authors listed] [No authors listed] Int J Radiat Oncol Biol Phys. 2021 Oct 1;111(2):587. doi: 10.1016/j.ijrobp.2021.06.003. Int J Radiat Oncol Biol Phys. 2021. PMID: 34473989 No abstract available.

No abstract available

Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer.
Marcq G, Souhami L, Cury FL, Salimi A, Aprikian A, Tanguay S, Vanhuyse M, Rajan R, Brimo F, Mansure JJ, Kassouf W. Marcq G, et al. Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):738-741. doi: 10.1016/j.ijrobp.2020.12.033. Epub 2021 Jan 6. Int J Radiat Oncol Biol Phys. 2021. PMID: 33421558 Clinical Trial.